Reports
Sale
Guillain-Barre Syndrome Treatment Market Size, Share, Trends: By Type: Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Others; By Treatment; By Route of Administration; By Gender; By Patient Type; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Guillain-Barre Syndrome Treatment Market Size
The Guillain-Barre syndrome treatment market is estimated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, driven by increasing technological advancements propelling the market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Guillain-Barre Syndrome Treatment Market Outlook
- The market growth is driven by the emphasis on developing new and effective treatment modalities that focus on specific molecular targets of Guillain-Barre syndrome pathology.
- Joint ventures between academic and biotech companies aimed at integrating system-oriented programmes to offer targeted therapeutic strategies is amongst major market trends.
- Increasing efforts to apply HEOR strategies for assessing the long-term effectiveness and value-based outcomes of the GBS therapeutic interventions is also expected to boost the market value in coming years.
Guillain-Barre Syndrome Treatment Market Overview
Guillain-Barré Syndrome (GBS) is an autoimmune, polycentral, rare peripheral nerve disorder, which affects large nerves outside the brain and spinal cord. It can lead to muscle weakness and paralysis, amongst a range of other fatal complications. Usually, the initial signs include non-serious shocks and initial paralysis of legs, which later affects arms and upper body parts. Although the cause of this diseases unknown, GBS syndrome commonly develops after an individual has been exposed to a bacterial or viral infection. Possible options for treatment include the identification of entirely differentiated neurological techniques to manage some of the symptoms, minimize inflammation, and encourage axon regeneration.
Guillain-Barre Syndrome Treatment Market Growth Drivers
Increased cases of Guillain-Barré Syndrome Drive the Market in the Forecast Period
The rising prevalence of the condition is driving the demand for effective treatment alternatives. GBS syndrome is generally associated with proximal and distal muscle weakness especially of the limbs, with accompanying diminished or absent reflexes, sensorial changes, and rarely cranial neuropathies. This particularly, is a very fast developing disease because of nerve inflammation that results in paralyzed muscles and muscles weakness and often results to total paralysis in patients. While the specific factor has not yet been determined, GBS syndrome is mostly triggered by a digestive or respire infection. To prevent comorbidities and mortality rates associated with the condition, researchers and scientists are actively working on developing precise and efficient treatment.
Modernization of Medical Equipment Leading to Accurate Diagnosis
As the technology progresses, diagnosis of GBS syndrome has become comparatively accurate and much faster. For instance, neuroimaging technology enabled with refined protocols and specialized biomarkers have all made it easier for healthcare professionals to diagnose GBS syndrome. Prompt and accurate diagnosis is highly essential since it can assist in early treatment of the disease and avoid severe consequences. Such advancements in technology are therefore instrumental to provide better and efficient diagnostics for GBS syndrome and boost its treatment market as well.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Guillain-Barre Syndrome Treatment Market Trends
| Key Trends | Impact |
| Focus on Gene Therapy and Regenerative Medicine | The adoption of new treatments including gene therapy which involve correcting abnormal genes with the help of genetic material is amongst major trends. Regenerative medicine is another option being explored for GBS syndrome treatment. It includes damaged nerve replacement to offer better functioning nerves. For instance, CRISPR-Cas9 can help in the targeting and editing of mutations. The utilization of such techniques can lead to symptom alleviation as well as reduced side effects. |
| Biomarker-Driven Personalized Medicine | Anti-ganglioside antibodies and cytokine profile identification has brought a new dimension in GBS syndrome treatment. These biomarkers make it possible to develop personalized treatment regimens based on the patient’s individual biology in a bid to increase the effectiveness while reducing the impact of side effects. This strategy is driving market growth as it helps in providing targeted care to a patient based on their prognosis. |
| Adoption of Health Economic and Outcomes Research (HEOR) | Analyzing the efficacy of advanced therapies through HEOR is major market trend. HEOR based studies can offer insights regarding the economic value and long-term impacts of new GBS syndrome treatments, promising significant savings for both patient and provider, and better patient outcomes. This also includes the potential of new treatments to win approval. |
| Growing Geriatric Population | Ageing is a critical factor that enhances the manifestation of an immunological disease such as multiple sclerosis and severe motor axonal neuropathy. GBS syndrome is extremely recurrent in the adult population, especially male individuals. Therefore, rising geriatric population across the globe is expected to impact significantly. |
Recent Developments in Guillain-Barre Syndrome Treatment Market
In October, 2023 Annexon Inc. achieved a significant milestone as the European Medicine Agency (EMA) granted orphan drug designation to ANX005 for treating Guillain-Barré Syndrome (GBS). ANX005, a humanized monoclonal antibody, targets C1q to stop complement-mediated inflammation and neuronal damage in GBS syndrome. The designation was based on a notable comparative efficacy analysis showing early muscle strength improvement compared to standard IVIg therapy, promising enhanced outcomes for GBS syndrome patients.
In March 2023, Hansa Biopharma completed enrollment in its phase 2 study of imlifidase in GBS syndrome. The phase II evaluated safety, tolerability, and efficacy in combination with standard (intravenous immunoglobulin) IVIg therapy. It was administered to patients before the standard of care.
Guillain-Barre Syndrome Treatment Market Segmentation
Market Breakup by Type
- Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
- Miller Fisher Syndrome (MFS)
- Acute Motor Axonal Neuropathy (AMAN)
Market Breakup by Treatment
- Intravenous Immunoglobulin
- Plasma Exchange (Plasmapheresis)
- Others
Market Breakup by Route of Administration
- Parenteral
- Oral
- Others
Market Breakup by Gender
- Male
- Female
Market Breakup by Patient Type
- Adult
- Pediatric
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Guillain-Barre Syndrome Treatment Market Share
Intravenous Immunoglobulin is Anticipated to the Have Largest Market Share Based on Treatment
Based on the market segmentation by treatment, the market is divided into intravenous immunoglobulin, plasma exchange (plasmapheresis) and others. Intravenous immunoglobulin (IVIG) involves the application of an antibodies solution to manage the condition. The preference for this treatment can also be attributed to its faster absorption, leading to higher efficacy compared to other options. Wide availability of the IVIG products like Gamunex, Gammagard and Privigen also boosts the market share of this segment. Further, the rising research activities on IVIG are anticipated to contribute to the overall GBS syndrome treatment market growth.
Males Lead the Market Share Based on Gender
Based on gender, the segmentation includes males and females. The male to female incidence ratio is 1.5:1 for the condition. Hence, males are likely to lead the market share in the forecast period, owing to higher susceptibility of disease occurrence.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Guillain-Barre Syndrome Treatment Market by Region
Regionally, the market report offers insights on United States, EU-4 (Germany, France, Italy, and Spain), United Kingdom, Japan as well as India. The annual incidence in the United States population is around 1.2-3 per 100,000 individuals, out of which 8.6 cases per 100,000 occur at the age of 70-79 years. High prevalence rate, shift in the lifestyle and a rise in the per capita health expenditure are likely to impact the United States market share positively in the forecast period.
In United States and European countries, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) has higher occurrence, while countries like Japan witnesses more cases of acute motor axonal neuropathy (AMAN). According to epidemiologic studies, Japan has a greater percentage of GBS syndrome cases in comparison to United States and European countries. With a robust medical research and development infrastructure, the region is expected to lead the market share for GBS syndrome treatment in the forecast period.
Leading Players in the Global Guillain-Barre Syndrome Treatment Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding, and investment analysis, along with partnership and collaborations analysis by the leading players. The major companies in the market are as follows:
CSL Behring
Established in the year 2007 and headquartered in Pennsylvania, United States, this company has a special neuromuscular therapy line with intravenous immunoglobulins (IVIg) for GBS syndrome treatment.
OctaPharma AG
Founded in 1983 and headquartered in Lachen, Swutzerland. The company’s plasma-derived immunoglobulin therapy specialises in GBS syndrome which include immunological disorders.
Annexon Biosciences
This is an American biotechnology company that was established in the year 2011 with its headquarters located in California, United States. The company has a product pipeline under investigation for GBS syndrome.
Other market players include Cellenkos Inc., and Hansa Biopharma AB.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Gender |
|
| Breakup by Patient Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Guillain-Barre Syndrome Treatment Market
- What was the global Guillain-Barre syndrome treatment market value in 2023?
- What is the global Guillain-Barre syndrome treatment market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What are the major factors aiding the global Guillain-Barre syndrome treatment market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global Guillain-Barre syndrome treatment market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the Guillain-Barre syndrome treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
- What is the market segmentation based on type?
- What is the market breakup based on treatments?
- What is the market segmentation based on route of administration?
- What is the market breakup based on gender?
- What are the major end users in the market?
- What is the market breakup based on patient type?
- What are the major distribution channels?
- What factors influence the choice between intravenous immunoglobulin and plasma exchange as Guillain-Barre syndrome treatment options for patients?
- How does the preference for parenteral administration versus oral administration vary across different regions for Guillain-Barre syndrome treatment market?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Guillain-Barre Syndrome Treatment Market Overview – 8 Major Markets
3.1 Guillain-Barre Syndrome Treatment Market Historical Value (2017-2023)
3.2 Guillain-Barre Syndrome Treatment Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Guillain-Barre Syndrome Treatment Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Guillain- Barre Syndrome Treatment Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality, by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment seeking rate, by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Guillain-Barre Syndrome Treatment Market Landscape – 8 Major Markets
8.1 Guillain-Barre Syndrome Treatment: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Guillain-Barre Syndrome Treatment: Product Landscape
8.2.1 Analysis by Treatment
8.2.2 Analysis by Route of Administration
9 Guillain-Barre Syndrome Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Guillain- Barre Syndrome Treatment Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Guillain- Barre Syndrome Treatment Market Segmentation (2017-2032) - 8 Major Markets
12.1 Guillain-Barre Syndrome Treatment Market (2017-2032) by Type
12.1.1 Market Overview
12.1.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
12.1.3 Miller Fisher Syndrome (MFS)
12.1.4 Acute Motor Axonal Neuropathy (AMAN)
12.2 Guillain-Barre Syndrome Treatment Market (2017-2032) by Treatment
12.2.1 Market Overview
12.2.2 Intravenous Immunoglobulin
12.2.3 Plasma Exchange (Plasmapheresis)
12.2.4 Others
12.3 Guillain-Barre Syndrome Treatment Market (2017-2032) by Route of Administration
12.3.1 Market Overview
12.3.2 Parenteral
12.3.3 Oral
12.3.4 Others
12.4 Guillain-Barre Syndrome Treatment Market (2017-2032) by Gender
12.4.1 Market Overview
12.4.2 Male
12.4.3 Female
12.5 Guillain-Barre Syndrome Treatment Market (2017-2032) by Patient Type
12.5.1 Market Overview
12.5.2 Adult
12.5.3 Pediatric
12.6 Guillain-Barre Syndrome Treatment Market (2017-2032) by End User
12.6.1 Market Overview
12.6.2 Hospitals
12.6.3 Specialty Clinics
12.6.4 Others
12.7 Guillain-Barre Syndrome Treatment Market (2017-2032) by Distribution Channel
12.7.1 Market Overview
12.7.2 Hospital Pharmacies
12.7.3 Retail Pharmacies
12.7.4 Others
12.8 Guillain-Barre Syndrome Treatment Market (2017-2032) by Region
12.8.1 Market Overview
12.8.2 United States
12.8.3 EU-4 and the United Kingdom
12.8.3.1 Germany
12.8.3.2 France
12.8.3.3 Italy
12.8.3.4 Spain
12.8.3.5 United Kingdom
12.8.4 Japan
12.8.5 India
13 United States Guillain-Barre Syndrome Treatment Market (2017-2032)
13.1 United States Guillain-Barre Syndrome Treatment Market Historical Value (2017-2023)
13.2 United States Guillain-Barre Syndrome Treatment Market Forecast Value (2024-2032)
13.3 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by Type
13.3.1 Market Overview
13.3.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
13.3.3 Miller Fisher Syndrome (MFS)
13.3.4 Acute Motor Axonal Neuropathy (AMAN)
13.4 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by Treatment
13.4.1 Market Overview
13.4.2 Intravenous Immunoglobulin
13.4.3 Plasma Exchange (Plasmapheresis)
13.4.4 Others
13.5 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by Route of Administration
13.5.1 Market Overview
13.5.2 Parenteral
13.5.3 Oral
13.5.4 Others
13.6 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by Gender
13.6.1 Market Overview
13.6.2 Male
13.6.3 Female
13.7 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by Patient Type
13.7.1 Market Overview
13.7.2 Adult
13.7.3 Pediatric
13.8 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by End User
13.8.1 Market Overview
13.8.2 Hospitals
13.8.3 Specialty Clinics
13.8.4 Others
13.9 United States Guillain-Barre Syndrome Treatment Market (2017-2032) by Distribution Channel
13.9.1 Market Overview
13.9.2 Hospital Pharmacies
13.9.3 Retail Pharmacies
13.9.4 Others
14 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032)
14.1 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
14.3.3 Miller Fisher Syndrome (MFS)
14.3.4 Acute Motor Axonal Neuropathy (AMAN)
14.4 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by Treatment
14.4.1 Market Overview
14.4.2 Intravenous Immunoglobulin
14.4.3 Plasma Exchange (Plasmapheresis)
14.4.4 Others
14.5 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by Route of Administration
14.5.1 Market Overview
14.5.2 Parenteral
14.5.3 Oral
14.5.4 Others
14.6 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by Gender
14.6.1 Market Overview
14.6.2 Male
14.6.3 Female
14.7 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by Patient Type
14.7.1 Market Overview
14.7.2 Adult
14.7.3 Pediatric
14.8 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by End User
14.8.1 Market Overview
14.8.2 Hospitals
14.8.3 Specialty Clinics
14.8.4 Others
14.9 EU-4 and United Kingdom Guillain-Barre Syndrome Treatment Market (2017-2032) by Distribution Channel
14.9.1 Market Overview
14.9.2 Hospital Pharmacies
14.9.3 Retail Pharmacies
14.9.4 Others
15 Japan Guillain-Barre Syndrome Treatment Market
15.1 Japan Guillain-Barre Syndrome Treatment Market Historical Value (2017-2023)
15.2 Japan Guillain-Barre Syndrome Treatment Market Forecast Value (2024-2032)
15.3 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
15.3.3 Miller Fisher Syndrome (MFS)
15.3.4 Acute Motor Axonal Neuropathy (AMAN)
15.4 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by Treatment
15.4.1 Market Overview
15.4.2 Intravenous Immunoglobulin
15.4.3 Plasma Exchange (Plasmapheresis)
15.4.4 Others
15.5 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by Route of Administration
15.5.1 Market Overview
15.5.2 Parenteral
15.5.3 Oral
15.5.4 Others
15.6 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by Gender
15.6.1 Market Overview
15.6.2 Male
15.6.3 Female
15.7 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by Patient Type
15.7.1 Market Overview
15.7.2 Adult
15.7.3 Pediatric
15.8 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by End User
15.8.1 Market Overview
15.8.2 Hospitals
15.8.3 Specialty Clinics
15.8.4 Others
15.9 Japan Guillain-Barre Syndrome Treatment Market (2017-2032) by Distribution Channel
15.9.1 Market Overview
15.9.2 Hospital Pharmacies
15.9.3 Retail Pharmacies
15.9.4 Others
16 India Guillain-Barre Syndrome Treatment Market
16.1 India Guillain-Barre Syndrome Treatment Market (2017-2032) Historical Value (2017-2023)
16.2 India Guillain-Barre Syndrome Treatment Market (2017-2032) Forecast Value (2024-2032)
16.3 India Guillain-Barre Syndrome Treatment Market (2017-2032) by Type
16.3.1 Market Overview
16.3.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
16.3.3 Miller Fisher Syndrome (MFS)
16.3.4 Acute Motor Axonal Neuropathy (AMAN)
16.4 India Guillain-Barre Syndrome Treatment Market (2017-2032) by Treatment
16.4.1 Market Overview
16.4.2 Intravenous Immunoglobulin
16.4.3 Plasma Exchange (Plasmapheresis)
16.4.4 Others
16.5 India Guillain-Barre Syndrome Treatment Market (2017-2032) by Route of Administration
16.5.1 Market Overview
16.5.2 Parenteral
16.5.3 Oral
16.5.4 Others
16.6 India Guillain-Barre Syndrome Treatment Market (2017-2032) by Gender
16.6.1 Market Overview
16.6.2 Male
16.6.3 Female
16.7 India Guillain-Barre Syndrome Treatment Market (2017-2032) by Patient Type
16.7.1 Market Overview
16.7.2 Adult
16.7.3 Pediatric
16.8 India Guillain-Barre Syndrome Treatment Market (2017-2032) by End User
16.8.1 Market Overview
16.8.2 Hospitals
16.8.3 Specialty Clinics
16.8.4 Others
16.9 India Guillain-Barre Syndrome Treatment Market (2017-2032) by Distribution Channel
16.9.1 Market Overview
16.9.2 Hospital Pharmacies
16.9.3 Retail Pharmacies
16.9.4 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 Japan PMDA
17.1.4 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by Year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 CSL Behring
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Cellenkos Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.3.6 Certifications
23.4 Hansa Biopharma AB
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 OctaPharma AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Annexon Biosciences
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
24 Guillain-Barre Syndrome Treatment Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
*The supplier list is not exhaustive, we can provide analysis of companies as per custom request also
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER